| (Values in U.S. Thousands) | May, 2025 | Feb, 2025 | Nov, 2024 | Aug, 2024 | May, 2024 |
| Sales | 17,730 | 19,050 | 25,000 | 22,600 | 22,020 |
| Sales Growth | -6.93% | -23.80% | +10.62% | +2.63% | +35.51% |
| Net Income | -4,460 | 120 | -7,900 | 3,090 | 990 |
| Net Income Growth | -3,816.67% | +101.52% | -355.66% | +212.12% | +122.10% |
Theratechnologies Inc (THTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Theratechnologies, Inc. is a pharmaceutical company focusing on the development of therapeutic peptide products with an emphasis on growth-hormone releasing factor peptides. It's main product EGRIFTA is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy which is marketed primarily in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. Theratechnologies, Inc. is headquartered in Montreal, Canada.
Fiscal Year End Date: 11/30